HBV Immunogenic Composition for Sustained Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic hepatitis B, such as antiviral therapies and immunotherapies, are limited in their ability to induce potent and sustained immune responses, leading to temporary suppression of HBV replication and eventual viral rebound, with long-term efficacy hindered by drug resistance and incomplete immune response restoration.
Innovation Solution
Development of an immunogenic composition comprising specific polypeptides or nucleic acids encoding polymerase, core, and env moieties of HBV, designed to stimulate robust immune responses by encoding immunogenic domains and utilizing modified HBV proteins to enhance T-cell and humoral immunity, potentially combined with vector-based expression systems for sustained antigen presentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If antiviral therapies are used to suppress HBV replication, then viral load is reduced, but drug resistance develops and immune response is not restored
Solution Approach 1:
The patent segments the HBV antigen into multiple immunogenic domains (polymerase, core, and envelope proteins) and presents them through different expression vectors simultaneously. This multi-component approach targets multiple viral antigens to induce comprehensive immune responses while reducing the likelihood of resistance development compared to single-antigen therapies.
Solution Approach 2:
The patent uses composite immunogenic compositions combining multiple HBV antigen types (polymerase, core, envelope proteins) delivered through different vector systems. This composite approach creates a multifaceted immune stimulus that addresses both viral suppression and immune restoration while minimizing resistance risks.
2Reliability
If conventional immunotherapies are used to stimulate immune response, then some immune activation occurs, but responses are not potent or sustained enough to prevent viral rebound
Solution Approach 1:
The patent employs sustained expression vectors that continuously present HBV antigens to the immune system over extended periods. This continuous antigen presentation maintains persistent immune activation and memory cell formation, preventing the waning of immune responses that characterizes conventional therapies.
Solution Approach 2:
The patent creates a dynamic immune stimulation strategy where multiple antigen types are presented in combination, allowing the immune system to respond to diverse epitopes. This dynamic multi-antigen approach enhances both the potency and durability of immune responses compared to static single-antigen therapies.
3Quantity of substance
If viral replication is suppressed but immune response is not restored, then temporary control is achieved, but viral rebound occurs eventually
Solution Approach 1:
The patent applies preliminary immunogenic stimulation before viral rebound can occur, using multiple HBV antigen types to pre-activate and prime the immune system. This preliminary immune enhancement ensures that when viral suppression is lifted, the immune system is already primed to maintain control and prevent rebound.
Data Source
AI summary
The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.